TVTX
HealthcareTravere Therapeutics, Inc.
$38.11
$-1.41 (-3.57%)
Jan 5, 2026
Price History (1Y)
Analysis
Travere Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $3.41 billion and annual revenue of $435.83 million, it has established itself as a significant player in its industry. The company employs approximately 385 individuals. From a financial health perspective, Travere Therapeutics faces challenges in terms of profitability, with a gross margin of 49.4% and operating margin of 15.1%. However, the company's net income is negative, standing at -$88,543,000 over the trailing twelve months. The balance sheet reflects a debt-to-equity ratio of 448.25, indicating that debt constitutes a substantial portion of the company's capital structure. Additionally, Travere Therapeutics has cash reserves of $254.53 million and total debt of $329.75 million. The valuation context of Travere Therapeutics is characterized by a forward P/E ratio of 20.89 and a price-to-book ratio of 46.36. The company's revenue growth over the past year was substantial, increasing by 162.1%. However, the earnings growth rate is not available. Notably, the dividend yield is zero, and the payout ratio is also zero, indicating that no dividends are being paid out to shareholders.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $3.41B
- P/E Ratio
- N/A
- 52-Week High
- $42.13
- 52-Week Low
- $12.91
- Avg Volume
- 1.82M
- Beta
- 0.85
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 385